arXiv:2606.04020v1 Announce Type: cross Abstract: Splice-mediated drug resistance occurs in up to 40% of patients on targeted kinase inhibitors, yet state-of-the-art druggability tools operate on single structures and cannot compare across isoforms. We introduce SpliceBind, a graph neural network framework for isoform-aware druggability prediction. Beyond improving prediction accuracy (AUROC 0.703 vs. P2Rank 0.634, p = 0.026), we address a more fundamental question: when do structural methods succeed, and when must they fail? Systematic analysis of six clinically validated variants spanning fi
The development of advanced AI models like graph neural networks is enabling more sophisticated approaches to biological problems that were previously intractable, such as isoform-aware drug prediction.
This development could significantly improve the efficacy of targeted therapies by addressing a major cause of drug resistance, leading to better patient outcomes and more efficient drug discovery.
Drug discovery and development processes will incorporate isoform-aware predictive tools, moving beyond single-structure assumptions to account for the complexities of protein variants in disease.
- · Pharmaceutical companies
- · Biotech firms
- · Patients with targeted therapy resistance
- · AI in drug discovery
- · Traditional drug screening methods
- · Oncology patients with inadequate variant-aware treatment options
Improved success rates for drug candidates in clinical trials, especially for diseases with high protein isoform variability.
Increased investment in AI-driven computational biology and structural bioinformatics as core competencies for drug developers.
The acceleration of personalized medicine approaches, where drug selection is tailored to an individual's specific protein isoform profile.
This signal links to a primary source. Continuum Brief monitors and indexes it as part of the live intelligence stream — we do not republish source content.
Read at arXiv cs.LG